James Edgemond Sells 21,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 21,000 shares of the business’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $470.36, for a total transaction of $9,877,560.00. Following the completion of the sale, the chief financial officer owned 8,118 shares in the company, valued at $3,818,382.48. This represents a 72.12% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

James Edgemond also recently made the following trade(s):

• On Monday, November 10th, James Edgemond sold 21,000 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total transaction of $9,493,470.00.
• On Tuesday, November 4th, James Edgemond sold 21,000 shares of United Therapeutics stock. The shares were sold at an average price of $436.09, for a total transaction of $9,157,890.00.

United Therapeutics Stock Performance

United Therapeutics stock traded up $4.67 during trading hours on Tuesday, hitting $476.59. 599,870 shares of the stock were exchanged, compared to its average volume of 591,927. The stock has a market capitalization of $20.52 billion, a P/E ratio of 18.06, a P/E/G ratio of 4.96 and a beta of 0.77. United Therapeutics Corporation has a 12 month low of $266.98 and a 12 month high of $485.32. The business’s 50-day moving average is $433.93 and its two-hundred day moving average is $351.26.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.89 by $0.27. The company had revenue of $799.50 million during the quarter, compared to analysts’ expectations of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.39 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post 24.48 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

UTHR has been the subject of a number of research reports. Wells Fargo & Company raised their target price on United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Bank of America upped their target price on shares of United Therapeutics from $314.00 to $463.00 and gave the stock a “neutral” rating in a research report on Tuesday, September 2nd. Weiss Ratings restated a “buy (b-)” rating on shares of United Therapeutics in a research report on Thursday. Cantor Fitzgerald lifted their target price on United Therapeutics from $405.00 to $525.00 and gave the company an “overweight” rating in a research note on Wednesday, September 10th. Finally, HC Wainwright upped their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $503.90.

Institutional Trading of United Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in UTHR. Wilmington Savings Fund Society FSB boosted its position in shares of United Therapeutics by 125.6% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Chung Wu Investment Group LLC bought a new stake in United Therapeutics in the second quarter valued at about $29,000. Abich Financial Wealth Management LLC acquired a new position in United Therapeutics in the third quarter valued at about $44,000. SVB Wealth LLC bought a new position in United Therapeutics during the first quarter worth about $32,000. Finally, WealthCollab LLC boosted its holdings in United Therapeutics by 55.9% during the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.